Business Context and Reporting Period
Company: Aquestive Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 4, 2025
Principal Executive Offices: Warren, NJ
Reporting Period: This filing reports a specific event occurring on September 4, 2025, rather than a financial reporting period.
Key Financial Metrics
This Form 8-K filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing is a regulatory disclosure regarding a specific corporate event.
Material Changes
Regulatory Update for Anaphylm:
- The U.S. Food and Drug Administration (FDA) informed the Company that an advisory committee meeting is not required for Anaphylm (dibutepinephrine) Sublingual Film.
- This decision removes a potential procedural step in the regulatory review process.
Guidance, Outlook, and Management Commentary
Regulatory Timeline:
- The Prescription Drug User Fee Act (PDUFA) target action date for Anaphylm remains January 31, 2026.
- Management views the elimination of the advisory committee requirement as a positive development for the regulatory timeline, though the final action date has not changed.
- The filing notes that the information provided is not deemed "filed" for purposes of Section 18 of the Exchange Act, limiting liability exposure for the forward-looking statements contained in the press release.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for detailed management commentary.
- Confirm the current status of the Anaphylm New Drug Application (NDA) on the FDA website.
- Monitor subsequent filings for any changes to the January 31, 2026 PDUFA target action date.
- Review the Company's most recent 10-Q or 10-K for financial health metrics, as this 8-K does not provide them.